• Publications
  • Influence
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
BACKGROUND No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo-controlled,Expand
  • 2,035
  • 94
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
BACKGROUND The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international consensus meeting were to describe the optimalExpand
  • 704
  • 41
Malignant peripheral nerve sheath tumors
The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with and without neurofibromatosis type 1 (NF‐1).
  • 443
  • 29
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
  • P. Casali, J. Blay
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 May 2010
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/ year [1]. This only covers clinically relevant GISTs, since it is likely that aExpand
  • 453
  • 25
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
BACKGROUND Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastaticExpand
  • 995
  • 24
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival.Expand
  • 739
  • 24
Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project.
Sarcomas are a heterogeneous group of malignant neoplasms arising from mesenchymal cells which encompass dozens of histological types and can occur in virtually any anatomic site. They form one ofExpand
  • 178
  • 24
Role of macrophage targeting in the antitumor activity of trabectedin.
There is widespread interest in macrophages as a therapeutic target in cancer. Here, we demonstrate that trabectedin, a recently approved chemotherapeutic agent, induces rapid apoptosis exclusivelyExpand
  • 473
  • 21
Rhabdomyosarcoma in adults
The goal of the current study was to clarify treatment outcomes for adult patients with rhabdomyosarcoma (RMS). Published series have reported definitively worse results for adults with RMS comparedExpand
  • 264
  • 20
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used for pediatric and adult patients. The current retrospective analysis examined aExpand
  • 293
  • 19